iHub News
3月前
Balchem rises more than 4% after record Q4 and full-year performanceFebruary 20, 2026 8:24 AM
IH Market News
Balchem Corporation (NASDAQ:BCPC) reported fourth-quarter results that exceeded Wall Street expectations, sending shares up 4.46% in pre-market trading.Adjusted earnings per share came in at $1.31, ahead of the $1.18 consensus forecast. Revenue reached $263.6 million, surpassing analysts’ expectations of $259.6 million and marking a 9.8% increase compared with the same quarter last year.On a GAAP basis, net earnings for the quarter climbed 16.8% to $39.2 million. Adjusted EBITDA rose 8.1% to a record $67.9 million. Gross profit expanded to $93.9 million in dollar terms, although gross margin as a percentage of sales edged slightly lower due to higher input costs. The company generated $67.3 million in operating cash flow and $51.2 million in free cash flow during the quarter.Chairman, President and CEO Ted Harris underscored the company’s ongoing momentum, stating, “In the fourth quarter, Balchem’s strong growth trajectory continued. We delivered record fourth quarter net sales and adjusted EBITDA, with top and bottom line growth year over year in each of our three segments.”For full-year 2025, Balchem posted record net sales of $1.04 billion, up 8.8%, alongside record adjusted EBITDA of $274.9 million. Adjusted earnings per share increased to $5.15 from $4.37 in 2024. Free cash flow reached an all-time high of $173.6 million, supporting higher dividend payments and share repurchases.Harris added, “For the full year 2025, Balchem delivered another very strong year… allowing us to increase our dividend once again by a double digit percentage while further strengthening our balance sheet.”The company closed the year with $74.6 million in cash and a net leverage ratio of just 0.3x, leaving it well-positioned to pursue above-market growth opportunities in 2026 and beyond.Balchem Corporation stock price
Original: Balchem rises more than 4% after record Q4 and full-year performance
metropick
19年前
Q3 EARNINGS CALL NOV 5 at 2 PM EST...
http://biz.yahoo.com/pz/071022/129302.html
Press Release Source: Balchem Corporation
Balchem Corporation Announces Third Quarter 2007 Results and Quarterly Conference Call On November 5, 2007 At 2:00 PM ET
Monday October 22, 2:00 pm ET
NEW HAMPTON, N.Y., Oct. 22, 2007 (PRIME NEWSWIRE) -- Balchem Corporation (NasdaqGS:BCPC - News) today announced that a conference call will be held on Monday, November 5 at 2:00 PM Eastern Time (ET) to review third quarter and year-to-date 2007 results. Dino A. Rossi, President and CEO, and Frank Fitzpatrick, Chief Financial Officer, will host the call.
Quarterly results will be released to the market on Monday, November 5, at 9:30 AM (ET). The press release, and its accompanying financial exhibits, will also be available on the Company website, http://www.balchem.com, prior to the conference call.
We invite you to listen to the call by dialing toll-free (877) 407-8289 (Event #8) five minutes prior to the scheduled start time of the conference call. The conference call will be available for digital replay through Friday, November 9. To access the replay of the conference call, dial (877) 660-6853, use account #298 and conference ID#259297. Both account and conference ID numbers are required for replay access.
About Balchem Corporation
Balchem Corporation consists primarily of three business segments: ARC Specialty Products, Encapsulated/Nutritional Products, and BCP Ingredients, our unencapsulated feed supplements segment. Through ARC Specialty Products, Balchem provides specialty-packaged chemicals for use in healthcare and other industries. The Encapsulated/Nutritional segment provides proprietary microencapsulation solutions to an expanding variety of applications. BCP Ingredients manufactures and supplies choline chloride and derivatives used primarily in the poultry and swine industries.
Contact:
Balchem Corporation
Karin McCaffery, Executive Administration Manager
845-326-5600
kmccaffery@balchemcorp.com
metropick
19年前
Balchem Announces Q2 Conference Call August 1
http://biz.yahoo.com/pz/070719/123316.html
Balchem Corporation Announces Quarterly Conference Call Second Quarter 2007 Results August 1, 2007 Time: 2:00 PM ET
NEW HAMPTON, N.Y., July 19, 2007 (PRIME NEWSWIRE) -- Balchem Corporation (NasdaqGS:BCPC - News) today announced that a conference call will be held on Wednesday, August 1, at 2:00 PM Eastern Time (ET) to review second quarter 2007 results. Dino A. Rossi, President and CEO, and Frank Fitzpatrick, Chief Financial Officer, will host the call.
Quarterly results will be released to the market on Wednesday, August 1, at 9:30 AM (ET). The press release, and its accompanying financial exhibits, will also be available on the Company website, http://www.balchem.com, prior to the conference call.
We invite you to listen to the call by dialing toll-free (877) 407-8289 (Event #8) five minutes prior to the scheduled start time of the conference call. The conference call will be available for digital replay through Monday, August 6. To access the replay of the conference call, dial (877) 660-6853, use account #298 and conference ID#249459. Both account and conference ID numbers are required for replay access.
metropick
19年前
Balchem Completes Acquisition
http://www.balchem.com/core/newsletter_details.asp?ArticleID=323
Balchem Completes Acquisition of Akzo Nobel’s European-based Choline Chloride and Methylamines Businesses at Marano Ticino, Italy
New Hampton, New York. May 1, 2007. Balchem Corporation (NASDAQ:BCPC) today announced the completion of its acquisition of the European-based choline chloride and methylamines businesses of Akzo Nobel Chemicals S.p.A. in Marano Ticino. Balchem and Akzo Nobel originally announced this acquisition on April 2, 2007. This facility and business will be operated by Balchem Italia, S.r.l. and employs approximately 75 people in Marano Ticino. In addition, a three person sales force operating out of Balchem Trading B.V. in the Netherlands will have primary responsibility for the marketing, sales and distribution of certain products produced at the facility. In 2006, the Akzo Nobel Marano Ticino business had approximately $35 million dollars (U.S.) in sales.
Balchem is a worldwide leader in the production and sales of various choline chloride products, which are nutritional additives to animal feed and human food products. Methylamines are a primary building block for the manufacture of choline products and have several other chemical applications.
Dino Rossi, Balchem’s President, CEO and Chairman added, “The closing of this transaction marks a tremendous step forward in the evolution and growth of Balchem. This acquisition provides a direct platform for Balchem to meet the growing market needs of methylamines, choline chloride and derivative products for customers via improved global sourcing, regulatory support, marketing and distribution capabilities.”
For more details regarding the closing of this transaction, including the provisional purchase price, see Balchem's Form 8-K filing to be submitted to US Securities and Exchange Commission (www.sec.gov).
metropick
19年前
My favorite part of this article is: "This revenue, when added to Balchem's 2006 result and its other acquisition in 2007, raises Balchem revenues on a pro forma basis for 2006 to approximately $175 million from $101 million."
Taking into account purely organic growth & identical profit margins, based on past data (see chart in iBox 2004-2006), I am looking for earnings of over $27 million (or $1.56/share), which would put today's p/e at 12. A correction to the current p/e would put this stock at $29/share.
Not a bad rate of return!!! See ya there!!!
metropick
19年前
Balchem Corporation to Purchase the Marano Ticino Choline Chloride and Methylamines Business of Akzo Nobel
A follow up from my last post...
http://www.balchem.com/core/newsletter_details.asp?ArticleID=319
New Hampton, New York, April 2, 2007 - Balchem Corporation (NASDAQ: BCPC) today announced that its European subsidiary, Balchem, B.V. entered into an agreement under which it will acquire the choline chloride and methylamines businesses located in Marano Ticino, Italy from Akzo Nobel Chemicals S.p.A. Akzo Nobel is a global leader in the chemical industry, and its Marano Ticino operation employs approximately eighty people, manufacturing and distributing choline, methylamines and derivative products to customers around the world.
"This acquisition provides a production platform that will enable us to better serve the expanding worldwide human and animal choline chloride demand and it also adds a direct commercial European presence, which we now deem necessary. In addition to choline nutritional products, we gain access to production and technology for methylamines, metam sodium and other products for various industrial applications. This platform should provide many opportunities for Balchem to leverage its global growth plans,” said Dino A. Rossi, President, CEO and Chairman of the Board of Directors of Balchem.
In 2006, this Akzo operation realized approximately US $35 million in revenue. This revenue, when added to Balchem's 2006 result and its other acquisition in 2007, raises Balchem revenues on a pro forma basis for 2006 to approximately $175 million from $101 million.
Choline chloride is an essential nutrient for optimum animal growth, and is integral in building, regulating, and maintaining cell membrane integrity and porosity. It also acts as a lipotropic agent, which aids in the utilization and outward transport of fat in the liver. Choline chloride and its derivatives are also used in many other industrial applications. Methylamines are used as raw materials for the production of choline chloride and also widely used in many chemical and industrial applications.
metropick
19年前
Balchem Corporation Purchases Certain Business Assets of Chinook Global Limited
With this acquisition, I think Balchem will become the primary choline (vitamin B4) producer in North America... Also, they just announced earlier this month that they would be purchasing Akzo's choline / methyl-amines business in Italy... thus vastly increasing their global market share of choline in just the past few weeks.
Good stuff. Good stuff indeed.
http://www.balchem.com/core/newsletter_details.asp?ArticleID=316
New Hampton, New York - March 19, 2007 - Balchem Corporation (NASDAQ: BCPC) today announced that its subsidiary, BCP Ingredients, Inc. acquired certain choline chloride business assets of Chinook Group Limited of Sombra, Ontario, Canada. Financial terms will be disclosed in SEC filings relating to the transaction.
The acquisition will be integrated into BCP Ingredients’ existing choline chloride manufacturing operations in Verona, Missouri and St. Gabriel, Louisiana. “We are excited at the prospect of enhancing our ability to service the animal nutrition marketplace from our strategically located facilities. Global market dynamics require suppliers to gain scale in order to effectively and economically produce and distribute quality product. Our focused efforts on choline will enable us to contribute to the development of efficient, high performance diets formulated by nutritional experts," said Balchem President and CEO, Dino Rossi. "This acquisition is one more building block in our growth strategy for the animal nutrition and health industry, and a wonderful opportunity for Balchem to implement, and for the consumer to realize, more fully, our synergies which are derived across multiple integrated business segments.”
Choline chloride is an essential nutrient for optimum animal growth, and is integral in building, regulating, and maintaining cell membrane integrity and porosity. It also acts as a lipotropic agent, which aids in the utilization and outward transport of fat in the liver. Choline and choline derivatives are also used in many other industrial applications.
Hot Features
プレミアム
登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。
whytestocks
6年前
Penny Roger$
14年前
メールアドレスで登録
